CONMED (CNMD) Expected to Announce Earnings on Wednesday

CONMED (NYSE:CNMD) will likely be posting its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect CONMED to post earnings of $0.81 per share and revenue of $313.38 million for the quarter. CONMED has set its FY 2025 guidance at 4.250-4.400 EPS.

CONMED (NYSE:CNMD) last posted its earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.14. CONMED had a return on equity of 14.31% and a net margin of 10.13%. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Trading Up 0.5 %

CONMED stock opened at $50.94 on Tuesday. The stock has a market cap of $1.58 billion, a P/E ratio of 12.01, a PEG ratio of 1.83 and a beta of 1.28. CONMED has a fifty-two week low of $46.00 and a fifty-two week high of $78.58. The firm’s fifty day moving average price is $56.75 and its 200-day moving average price is $65.09. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.06 and a current ratio of 2.30.

CONMED Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, April 4th. Stockholders of record on Friday, March 14th were issued a $0.20 dividend. The ex-dividend date was Friday, March 14th. This represents a $0.80 annualized dividend and a dividend yield of 1.57%. CONMED’s payout ratio is currently 18.87%.

Analyst Ratings Changes

CNMD has been the topic of several research analyst reports. JPMorgan Chase & Co. cut shares of CONMED from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $85.00 to $70.00 in a report on Thursday, February 6th. Needham & Company LLC decreased their price target on shares of CONMED from $97.00 to $91.00 and set a “buy” rating on the stock in a report on Thursday, February 6th. Stifel Nicolaus cut CONMED from a “buy” rating to a “hold” rating and reduced their target price for the company from $75.00 to $55.00 in a research note on Monday. Finally, Wells Fargo & Company reduced their target price on CONMED from $74.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 6th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $73.20.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.